Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

Patent metadata

Field	Value
Publication number	US-10814013-B2
Application number	US-201213562879-A
Country	US
Kind code	B2
Filing date	Jul 31, 2012
Priority date	Oct 5, 2006
Publication date	Oct 27, 2020
Grant date	Oct 27, 2020

Abstract

Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

First claim

What is claimed is:

1. A method of imaging the heart of a subject with a cardiovascular disease comprising:
(a) obtaining a metal ion-labeled-chelator targeting ligand conjugate, the conjugate being between about 90% and about 99.9% pure as measured by HPLC using ELSD detection, wherein the conjugate has been previously prepared by a synthetic method comprising:
(1) conjugating, in an organic medium, a protected ethylenedicysteine of the following formula:

to a glucosamine, wherein:
A and D are each a protected thiol;
B and C are each a protected tertiary amine;
and the conjugation is via an amide bond formed between a —COOH group of the protected ethylenedicysteine and the amino group of the glucosamine to form a protected ethylenedicysteine glucosamine;

(2) removing each protecting group, in one or more steps, from the protected ethylenedicysteine glucosamine to form ethylenedicysteine glucosamine (EC-G); and
(3) chelating a metal ion to the EC-G to form a metal ion labeled-chelator-targeting ligand conjugate;

(b) administering to the subject a pharmaceutically or diagnostically effective amount of the conjugate; and
(c) imaging the heart of the subject to detect a signal from the metal ion of the conjugate.

2. The method of claim 1 , further comprising performing one or more additional diagnostic or imaging procedures to evaluate the subject for a cardiovascular disease.

3. The method of claim 1 , wherein the cardiovascular disease is a myocardial infarction, congestive heart failure, cardiomyopathy, valvular heart disease, an arrhythmia, congenital heart disease, angina pectoris, noncardiac circulatory congestion, systolic heart failure, heart failure with normal systolic function, or right-sided heart failure.

4. The method of claim 3 , wherein the cardiovascular disease is a myocardial infarction, myocardial ischemia, or angina pectoris.

5. The method of claim 1 , wherein the metal ion labeled-chelatortargeting ligand conjugate is 99m Tc-ECglucosamine, 188 Re-EC-glucosamine, or 187 Re-EC-glucosamine.

6. The method of claim 1 , wherein the organic medium comprises a polar solvent.

7. The method of claim 1 , wherein the organic medium comprises dimethylformamide, dimethylsulfoxide, dioxane, methanol, ethanol, hexane, methylene chloride, acetonitrile, tetrahydrofuran, or a mixture thereof.

8. The method of claim 1 , wherein the synthetic method further comprising at least one purification step, wherein the purification step is silica gel column chromatography, HPLC, or a combination thereof.

9. The method of claim 1 , wherein the protected ethylenedicysteine glucosamine is EC-Benzhydrol-Cbz-Glucosamine.

10. The method of claim 1 , wherein the metal ion is a radionuclide.

11. The method of claim 1 , wherein the subject is a human.

12. The method of claim 1 , wherein the signal is detected using a technique selected from the group consisting of PET, PET/CT, CT, SPECT, SPECT/CT, MRI, and optical imaging.

Assignees

• Yang David J
• Yu Dongfang
• Thompson Andrew S
• Rollo F David
• Univ Texas
• Cell Point Llc

Inventors

• Yang David J
• Yu Dongfang
• Thompson Andrew S
• Rollo F David

Classifications

• A61K51/0491

  Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers · CPC title

• A61K49/0002 Primary

  General or multifunctional contrast agents, e.g. chelated agents · CPC title

• A61K49/06

  Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K49/00

  Preparations for testing in vivo · CPC title